Abilify® is an atypical antipsychotic medication prescribed to treat schizophrenia, major depressive disorder, bipolar I, irritability associated with autistic disorder and Tourette’s disorder. On May 7, 2018, the Supreme Court designated all pending and future New Jersey state court actions against Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company alleging injuries as a result of the use of Abilify as multicounty litigation and assigned the actions to Atlantic County.